Tyra’s dabogratinib advances to phase III for MIBC
Dabogratinib, an oral FGFR3 inhibitor, reported phase II efficacy and safety in intermediate-risk MIBC, with 79% response and 64% CR rates at 60 mg. Phase III trials and UTUC expansion are planned.
Dabogratinib showed strong phase II efficacy and safety as an oral FGFR3 inhibitor for intermediate-risk MIBC, with 79% response and 64% complete response rates at 60 mg. The drug's convenience and tolerability are expected to position it as a likely first-line option, and phase III trials plus expansion into UTUC are planned.